Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

1. Orkin, C.
2. Oka, S.
3. Philibert, P.
4. Brinson, C.
5. Bassa, A.
6. Gusev, D.
7. Degen, O.
8. García, J.G.
9. Morell, E.B.
10. Tan, D.H.S.
11. D'Amico, R.
12. Dorey, D.
13. Griffith, S.
14. Thiagarajah, S.
15. St Clair, M.
16. Van Solingen-Ristea, R.
17. Crauwels, H.
18. Ford, S.L.
19. Patel, P.
20. Chounta, V.
21. Vanveggel, S.
22. Cutrell, A.
23. Van Eygen, V.
24. Vandermeulen, K.
25. Margolis, D.A.
26. Smith, K.Y.
27. Spreen, W.R.
28. Show all authors +